i-124 pgn650 for pet/ct

Name: i-124 pgn650 for pet/ct in Malignant Solid Tumor
Creator: Floatz
License: https://terminal.floatz.ai/terms

Malignant Solid Tumor

Peregrine PharmaceuticalsradiopharmaceuticalEarly Phase 1Dormant

38/ 100

Provisional rating · Methodology v0.2

Rating breakdown

45 Active assets in the Malignant Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Nivolumab Bristol-Myers Squibb	Phase 2	BB
CIS-DIAMMINEDICHLOROPLATINUM II Genmab	Phase 2	B
Irinotecan Tianjin Medical University Cancer Institute and Hospital	Phase 2	B
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER Eli Lilly and Company	Phase 2	B
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital	Phase 2	B

View all 50 →

Order a full diligence report on this asset.

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.